Head to Head Analysis: Vyome (HIND) and The Competition

Vyome (NASDAQ:HIND) is one of 29 public companies in the “Surgical, Medical, And Dental Instruments And Supplies” industry, but how does it weigh in compared to its peers? We will compare Vyome to similar companies based on the strength of its dividends, profitability, earnings, institutional ownership, risk, valuation and analyst recommendations.

Valuation and Earnings

This table compares Vyome and its peers revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Vyome	$8.01 million	-$7.13 million	-0.02
Vyome Competitors	$59.55 million	-$32.15 million	4.37

Vyome’s peers have higher revenue, but lower earnings than Vyome. Vyome is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a breakdown of current ratings for Vyome and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vyome	1	0	2	0	2.33
Vyome Competitors	77	77	157	6	2.29

Vyome presently has a consensus price target of $15.00, suggesting a potential upside of 451.47%. As a group, “Surgical, Medical, And Dental Instruments And Supplies” companies have a potential upside of 29.21%. Given Vyome’s stronger consensus rating and higher probable upside, equities analysts plainly believe Vyome is more favorable than its peers.

Insider and Institutional Ownership

22.1% of Vyome shares are held by institutional investors. Comparatively, 22.5% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are held by institutional investors. 33.0% of Vyome shares are held by insiders. Comparatively, 18.1% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Risk & Volatility

Vyome has a beta of 1.5, indicating that its stock price is 50% more volatile than the S&P 500. Comparatively, Vyome’s peers have a beta of 1.76, indicating that their average stock price is 76% more volatile than the S&P 500.

Profitability

This table compares Vyome and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vyome	-270.58%	-423.39%	-166.02%
Vyome Competitors	-672.41%	-133.75%	-59.01%

Summary

Vyome peers beat Vyome on 7 of the 13 factors compared.

About Vyome

ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.